Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion

Cancer Immunology, Immunotherapy

Volumn 59, Issue 10, 2010, Pages 1551-1560

  Goff, Stephanie L ^a,c   Johnson, Laura A ^b,c   Black, Mary A ^c   Xu, Hui ^c   Zheng, Zhili ^c   Cohen, Cyrille J ^c,d   Morgan, Richard A ^c   Rosenberg, Steven A ^c   Feldman, Steven A ^c  

^a Columbia University ^*  (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BAR ILAN UNIVERSITY   (Israel)

Author keywords

Gene therapy; Immunotherapy; MART 1; Melanoma; Retrovirus; T cell receptor

Indexed keywords

MELANOMA ANTIGEN RECOGNIZED BY T LYMPHOCYTE RECEPTOR 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE FUNCTION; GENE INSERTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; GENETIC VECTORS; HUMANS; LEUKOCYTES, MONONUCLEAR; MELANOMA; MICE; NEOPLASM PROTEINS; PLASMIDS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; TRANSDUCTION, GENETIC; UP-REGULATION;

EID: 77955554709     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0882-5     Document Type: Article

References (31)

1. Balch C, Atkins M, Sober A (2005) Cutaneous Melanoma. In: Devita V Jr, Helman S, Rosenber S (eds) Cancer: principles and practice of oncology, 7th edn. Lippincott Willliams & Wilkins, Philadelphia, pp 1754-1808
2. FO Smith SG Downey JA Klapper JC Yang RM Sherry, et al. 2008 Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines Clin Cancer Res 14 5610 5618 10.1158/1078-0432.CCR-08-0116 1:CAS:528: DC%2BD1cXhtVKmtr7O 18765555
3. ME Dudley JC Yang R Sherry MS Hughes R Royal, et al. 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 5233 5239 10.1200/JCO.2008.16.5449 1:CAS:528:DC%2BD1cXhsVyqsrbO 18809613
4. ME Dudley JR Wunderlich JC Yang RM Sherry SL Topalian, et al. 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2346 2357 10.1200/JCO.2005.00.240 1:CAS:528:DC%2BD2MXjsVyhsrs%3D 15800326 (Pubitemid 46218728)
5. ME Dudley JR Wunderlich PF Robbins JC Yang P Hwu, et al. 2002 Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 850 854 10.1126/science.1076514 1:CAS:528: DC%2BD38XotFSntbY%3D 12242449 (Pubitemid 35231542)
6. CJ Cohen Z Zheng R Bray Y Zhao LA Sherman, et al. 2005 Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR J Immunol 175 5799 5808 1:CAS:528:DC%2BD2MXhtFahurjN 16237072
7. B Engels W Uckert 2007 Redirecting T lymphocyte specificity by T cell receptor gene transfer-a new era for immunotherapy Mol Aspects Med 28 115 142 10.1016/j.mam.2006.12.006 1:CAS:528:DC%2BD2sXisVCnur4%3D 17307249
8. Y Zhao Z Zheng PF Robbins HT Khong SA Rosenberg, et al. 2005 Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines J Immunol 174 4415 4423 1:CAS:528:DC%2BD2MXisVChtLw%3D 15778407
9. MS Hughes YY Yu ME Dudley Z Zheng PF Robbins, et al. 2005 Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions Hum Gene Ther 16 457 472 10.1089/hum.2005.16. 457 1:CAS:528:DC%2BD2MXjvVamsrc%3D 15871677 (Pubitemid 40647143)
10. TM Clay MC Custer J Sachs P Hwu SA Rosenberg, et al. 1999 Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity J Immunol 163 507 513 1:CAS:528:DyaK1MXktF2rsbk%3D 10384155
11. RA Morgan ME Dudley JR Wunderlich MS Hughes JC Yang, et al. 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 126 129 10.1126/science.1129003 1:CAS:528:DC%2BD28XhtVCiurrK 16946036 (Pubitemid 44547756)
12. LA Johnson B Heemskerk DJ Powell Jr CJ Cohen RA Morgan, et al. 2006 Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes J Immunol 177 6548 6559 1:CAS:528:DC%2BD28XhtFSns7bK 17056587
13. LA Johnson RA Morgan ME Dudley L Cassard JC Yang, et al. 2009 Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 535 546 10.1182/blood-2009-03-211714 1:CAS:528:DC%2BD1MXpt1Wmsb0%3D 19451549
14. JM Boulter BK Jakobsen 2005 Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens Clin Exp Immunol 142 454 460 1:CAS:528:DC%2BD2MXhtlWqtrrM 16297157
15. CJ Cohen Y Zhao Z Zheng SA Rosenberg RA Morgan 2006 Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability Cancer Res 66 8878 8886 10.1158/0008-5472.CAN-06-1450 1:CAS:528:DC%2BD28XovF2ht7c%3D 16951205 (Pubitemid 44449206)
16. CJ Cohen YF Li M El-Gamil PF Robbins SA Rosenberg, et al. 2007 Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond Cancer Res 67 3898 3903 10.1158/0008-5472.CAN-06-3986 1:CAS:528:DC%2BD2sXkt1Kiurs%3D 17440104 (Pubitemid 46762178)
17. S Thomas S-A Xue M Cesco-Gaspere E San Jose DP Hart, et al. 2007 Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells J Immunol 179 5803 5810 1:CAS:528:DC%2BD2sXhtFylu7nE 17947653
18. J Kuball ML Dossett M Wolfl WY Ho R-H Voss, et al. 2007 Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood 109 2331 2338 10.1182/blood-2006-05-023069 1:CAS:528:DC%2BD2sXnslygsrk%3D 17082316 (Pubitemid 46425872)
19. G Bialer M Horovitz-Fried S Ya'acobi RA Morgan CJ Cohen, et al. 2010 Selected murine residues endow human TCR with enhanced tumor recognition J Immunol 184 11 6232 6241 10.4049/jimmunol.0902047 1:CAS:528:DC%2BC3cXmtFyqtrc%3D 20427762
20. L Reeves K Cornetta 2000 Clinical retroviral vector production: step filtration using clinically approved filters improves titers Gene Ther 7 1993 1998 10.1038/sj.gt.3301328 1:CAS:528:DC%2BD3cXoslWltbg%3D 11175310 (Pubitemid 32036764)
21. L Reeves P Smucker K Cornetta 2000 Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience Hum Gene Ther 11 2093 2103 10.1089/104303400750001408 1:CAS:528:DC%2BD3cXnsFOntbo%3D 11044911
22. SR Riddell PD Greenberg 1990 The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells J Immunol Methods 128 189 201 10.1016/0022-1759(90)90210-M 1:STN:280:DyaK3c3hslGlsQ%3D%3D 1691237 (Pubitemid 20120262)
23. J Wargo P Robbins Y Li Y Zhao M El-Gamil, et al. 2009 Recognition of NY-ESO-1 + tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression Cancer Immunol Immunother 58 383 394 10.1007/s00262-008-0562-x 1:CAS:528:DC%2BD1MXitlCjtQ%3D%3D 18677478
24. S Topalian D Solomon S Rosenberg 1989 Tumor-specific cytolysis by lymphocytes infiltrating human melanomas J Immunol 142 3714 3725 1:STN:280:DyaL1M3jsFWrtg%3D%3D 2785562
25. AE Foster M Marangolo MM Sartor SI Alexander M Hu, et al. 2004 Human CD62L-memory T cells are less responsive to alloantigen stimulation than CD62L + naive T cells: potential for adoptive immunotherapy and allodepletion Blood 104 2403 2409 10.1182/blood-2003-12-4431 1:CAS:528:DC%2BD2cXovVegt7Y%3D 15231569 (Pubitemid 39331840)
26. M Sanders W Malegapuru S Shaw 1988 Human naive and memory T cells: reinterpretation of helper-inducer and suppressor-inducer subsets Immunol Today 9 195 199 10.1016/0167-5699(88)91212-1 1:STN:280:DyaL1MzltFCmtw%3D%3D 2978373
27. L Gattinoni CA Klebanoff DC Palmer C Wrzesinski K Kerstann, et al. 2005 Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells J Clin Investig 115 1616 1626 10.1172/JCI24480 1:CAS:528:DC%2BD2MXkvF2lsro%3D 15931392 (Pubitemid 40814670)
28. JM Boulter M Glick PT Todorov E Baston M Sami, et al. 2003 Stable, soluble T-cell receptor molecules for crystallization and therapeutics Protein Eng 16 707 711 10.1093/protein/gzg087 1:CAS:528:DC%2BD3sXosVeqsr8%3D 14560057
29. J Kuball B Hauptrock V Malina E Antunes R-H Voss, et al. 2009 Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain J Exp Med 206 463 475 10.1084/jem.20082487 1:CAS:528:DC%2BD1MXit1Kju78%3D 19171765
30. L Gattinoni DJ Powell Jr SA Rosenberg NP Restifo 2006 Adoptive immunotherapy for cancer: building on success Nat Rev Immunol 6 383 393 10.1038/nri1842 1:CAS:528:DC%2BD28XjslOgsrw%3D 16622476
31. CS Hinrichs A Kaiser CM Paulos L Cassard L Sanchez-Perez, et al. 2009 Type 17 CD8+ T cells display enhanced antitumor immunity Blood 114 596 599 10.1182/blood-2009-02-203935 1:CAS:528:DC%2BD1MXpt1Wmtr4%3D 19471017